PLIANT THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
PLRX$0.80-1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Gain Loss
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Revenue | $1,580 | $9,685 | $7,572 |
| Operating expenses: | |||
| Research and development | (127,797) | (96,936) | (77,549) |
| General and administrative | (57,928) | (39,949) | (27,558) |
| Total operating expenses | (185,725) | (136,885) | (105,107) |
| Loss from operations | (184,145) | (127,200) | (97,535) |
| Interest and other income (expense), net | 24,076 | 4,670 | 272 |
| Interest expense | (1,267) | (791) | — |
| Net loss | $(161,336) | $(123,321) | $(97,263) |
| Net loss per share - basic and diluted | $(2.75) | $(2.94) | $(2.71) |
| Weighted average shares used in computing net loss per share - basic and diluted | 58,719,083 | 42,015,908 | 35,846,421 |
| Comprehensive loss: | |||
| Net loss | $(161,336) | $(123,321) | $(97,263) |
| Net unrealized gain (loss) on short-term investments | 2,303 | (1,757) | (169) |
| Total other comprehensive gain (loss) | 2,303 | (1,757) | (169) |
| Comprehensive loss | $(159,033) | $(125,078) | $(97,432) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.